This appears to be an example of how NOT to analyse an early stage biotech. I'm not sure how you got to a 12c valuation as you did not show your work, however if it is based on your 'takeaways' it is completely misguided. Could you please justify how P/E, ROA, ROCE, ROE, 2023 revenue, short term profitability or cashflow have any bearing on valuation of this type of company at this stage?
If your valuation is not based on your 'takeaways', please provide working so we can assess fully.
My analysis and intrinsic value of CHM March 2022, page-12
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.72K | 2.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2757364 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15260220 | 25 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |